BCAX
Bicara Therapeutics Inc. Common Stock · Healthcare · Biotechnology
动量输入(同类管理人):
持有人广度 — ·
股份流向 — ·
净新建仓位 +20.0%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q3 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 1.54M | 新增 | $39.20M | 0.0% | New | 1 | SEC ↗ |
| 2 | Adage Capital Partners ✦ | 800.00K | 新增 | $20.38M | 0.0% | New | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 763.94K | 新增 | $19.46M | 0.0% | New | 1 | SEC ↗ ×3 |
| 4 | Point72 Asset Management ✦ | 371.96K | 新增 | $9.47M | 0.0% | New | 1 | SEC ↗ |
| 5 | Millennium Management ✦ | 299.56K | 新增 | $7.63M | 0.0% | New | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 234.12K | 新增 | $5.96M | 0.0% | New | 1 | SEC ↗ |
| 7 | Norges Bank ✦ (被动) | 70.00K | 新增 | $1.78M | 0.0% | New | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (被动) | 48.64K | 新增 | $1.24M | 0.0% | New | 1 | SEC ↗ |
| 9 | Soros Fund Management ✦ | 20.00K | 新增 | $509,400 | 0.0% | New | 1 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 9.00K | 新增 | $229,230 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| T. Rowe Price | $39.20M | 0.0% |
| Adage Capital Partners | $20.38M | 0.0% |
| Wellington Management | $19.46M | 0.0% |
| Point72 Asset Management | $9.47M | 0.0% |
| Millennium Management | $7.63M | 0.0% |
| Citadel Advisors | $5.96M | 0.0% |
| Norges Bank | $1.78M | 0.0% |
| Geode Capital Management | $1.24M | 0.0% |
| Soros Fund Management | $509,400 | 0.0% |
| Two Sigma Investments | $229,230 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 146 持有人, 71.07M 股份, $1.23B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer, Director · 14.06K 股 · $320,053
Officer, Director · 3.44K 股 · $80,663
Officer, Director · 10.00K 股 · $279,750
Officer · 12.50K 股 · $349,591
Officer, Director · 18.75K 股 · $524,533
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论